Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS‐LSIL Triage Study

Only a subset of women with human papillomavirus (HPV) infections will become seropositive, and the factors influencing seroconversion are not well understood. We used a multiplex serology assay in women with mildly abnormal cytology results to examine seroreactivity to oncogenic HPV genotypes. An unbiased subset of women in the atypical squamous cell of undetermined significance /low‐grade squamous intraepithelial lesion Triage Study provided blood samples at trial enrollment for serological testing. A Luminex assay based on glutathione s‐transferase‐L1 fusion proteins as antigens was used to test seroreactivity against eight carcinogenic HPV genotypes (16, 18, 31, 33, 35, 45, 52 and 58). We analyzed the relationship between seroprevalence in women free of precancer (N = 2,464) and HPV DNA status, age, sexual behavior and other HPV‐related risk factors. The overall seroprevalence was 24.5% for HPV16 L1 and ∼20% for 18L1 and 31L1. Among women free of precancer, seroprevalence peaked in women less than 29 years and decreased with age. Type‐specific seroprevalence was associated with baseline DNA detection for HPV16 (OR = 1.36, 95%CI: 1.04–1.79) and HPV18 (OR = 2.31, 95%CI: 1.61–3.32), as well as for HPV52 and HPV58. Correlates of sexual exposure were associated with increased seroprevalence across most genotypes. Women who were current or former smokers were less likely to be seropositive for all eight of the tested oncogenic genotypes. The multiplex assay showed associations between seroprevalence and known risk factors for HPV infection across nearly all tested HPV genotypes but associations between DNA‐ and serostatus were weak, suggesting possible misclassification of the participants' HPV serostatus.

[1]  S. Wacholder,et al.  Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. , 2012, The Journal of infectious diseases.

[2]  A. Combita,et al.  Age-Specific Seroprevalence of Human Papillomavirus 16, 18, 31, and 58 in Women of a Rural Town of Colombia , 2011, International Journal of Gynecologic Cancer.

[3]  M. Pawlita,et al.  Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. , 2011, The Journal of general virology.

[4]  S. Wacholder,et al.  A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. , 2011, The Journal of infectious diseases.

[5]  S. Wacholder,et al.  Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. , 2010, Journal of the National Cancer Institute.

[6]  S. Wacholder,et al.  Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica , 2010, Sexually transmitted diseases.

[7]  M. Pawlita,et al.  Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam , 2010, Sexually transmitted diseases.

[8]  C. Wheeler,et al.  Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. , 2010, Cancer research.

[9]  S. Wacholder,et al.  Determinants of seropositivity among HPV-16/18 DNA positive young women , 2010, BMC infectious diseases.

[10]  J. Dillner,et al.  Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. , 2010, The Journal of general virology.

[11]  M. Schiffman,et al.  The Use of Human Papillomavirus Seroepidemiology to Inform Vaccine Policy , 2009, Sexually transmitted diseases.

[12]  C. Poole,et al.  Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis , 2009 .

[13]  C. Poole,et al.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[14]  M. Stanley.  Immunobiology of HPV and HPV vaccines. , 2008, Gynecologic oncology.

[15]  Joakim Dillner,et al.  Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection , 2008, Scandinavian journal of infectious diseases.

[16]  K. Jansen,et al.  Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics , 2008, Acta obstetricia et gynecologica Scandinavica.

[17]  M. Pawlita,et al.  Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. , 2008, The Journal of general virology.

[18]  S. Franceschi,et al.  Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  J. Rader,et al.  Human papillomaviruses target the double-stranded RNA protein kinase pathway. , 2006, The Journal of general virology.

[20]  S. Marshall,et al.  Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus , 2006, International journal of cancer.

[21]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[22]  S. Marshall,et al.  Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. , 2006, American journal of epidemiology.

[23]  S. Tatti,et al.  Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study , 2005, International Journal of Gynecologic Cancer.

[24]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[25]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[26]  M. Sherman,et al.  Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica , 2004, British Journal of Cancer.

[27]  M. Sherman,et al.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica , 2003, British Journal of Cancer.

[28]  M. Schiffman,et al.  Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. , 2003, American journal of obstetrics and gynecology.

[29]  C. Fischbacher,et al.  IgG is higher in South Asians than Europeans: does infection contribute to ethnic variation in cardiovascular disease? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[31]  M. Pawlita,et al.  HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. , 2002, Journal of virological methods.

[32]  N. Kiviat,et al.  Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  P. Coursaget,et al.  Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes , 2001, Journal of Clinical Microbiology.

[34]  P. Obeid,et al.  Effects of smoking on periodontal health: A review , 2000, Advances in therapy.

[35]  N. Kiviat,et al.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.

[36]  P. Puttfarcken,et al.  Acute and chronic nicotine exposures modulate the immune system through different pathways. , 2000, Toxicology and applied pharmacology.

[37]  A. Singer,et al.  The antigen‐presenting environment in normal and human papillomavirus (HPV)‐related premalignant cervical epithelium , 1999, Clinical and experimental immunology.

[38]  M. Kluger,et al.  Nicotine-Induced Modulation of T Cell Function , 1998 .

[39]  J. Gunsolley,et al.  The effect of race, smoking and immunoglobulin allotypes on IgG subclass concentrations. , 1997, Journal of periodontal research.

[40]  D. Lowy,et al.  Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. , 1996, The Journal of infectious diseases.

[41]  M. Lehtinen,et al.  Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. , 1996, The Journal of infectious diseases.

[42]  M. Sopori,et al.  Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. , 1996, Journal of immunology.

[43]  W. Blattner,et al.  Racial differences in serum immunoglobulin levels: Relationship to cigarette smoking, t‐cell subsets, and soluble interleukin‐2 receptors , 1995, Journal of clinical laboratory analysis.

[44]  P. Hersey,et al.  Low natural killer‐cell activity and immunoglobulin levels associated with smoking in human subjects , 1979, International journal of cancer.